India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. “The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s. IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing drug candidate. In phase 1 studies, IGC-AD1 shows potential to safely reduce the debilitating symptoms that impact millions of Alzheimer’s patients and their caregivers. Featuring a low dose of THC, the treatment is the first natural cannabis-based investigational drug being tested in human FDA trials to treat Alzheimer’s patients; it provides medical benefits without psychoactive effects. ‘As millions of Alzheimer’s patients continue to suffer from agitation, anxiety and depression, phase 2 clinical trials bring hope for a treatment,’ the company reports.”
To view the full article, visit https://cnw.fm/ttFBA
About India Globalization Capital Inc.
IGC develops advanced cannabinoid-based formulations for treating diseases and conditions including but not limited to Alzheimer’s, period cramps (dysmenorrhea), premenstrual syndrome (“PMS”) and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, that have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of the disease such as plaques and tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (“THC”) based formulation that is currently in a 146-person, phase 2B safety and efficacy clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). The company also markets two wellness brands, Holief and Sunday Seltzer. Holief targets women experiencing premenstrual syndrome and menstrual cramps and Sunday Seltzer is a lifestyle hemp-infused energy beverage brand. The company is headquartered in Maryland, USA, and has historically operated an infrastructure segment based in India.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://cnw.fm/IGC
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
[email protected]
CBDWire is part of the InvestorBrandNetwork.
